Vanguard refuses customer transactions for spot Bitcoin ETF
Asset management giant Vanguard has stated that they do not allow customers to trade spot Bitcoin ETFs because it is an immature asset class with little historical data, no intrinsic economic value, and no cash flow. It could potentially cause significant disruption in investment portfolios. Previously on January 15th, a spokesperson for Vanguard Group mentioned in an interview that besides being unable to purchase spot Bitcoin ETFs on the Vanguard platform, Vanguard will also no longer accept purchases of cryptocurrency products including Bitcoin futures ETFs. This change allows Vanguard Group to focus on providing a suite of core products and services in line with its commitment to meeting the needs of long-term investors.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A historic breakthrough in pancreatic cancer treatment! FDA approves RevMed's targeted new drug, with sales expected to exceed $9 billion by 2032.
The oral new drug daraxonrasib from RevMed has been officially approved by the FDA for market launch, with an annual list price exceeding $475,000. It is the first targeted drug aimed at the key molecular pathogenic mechanism of pancreatic cancer. Clinical trials show that the median survival time for patients almost doubled, increasing from 6.7 months to 13.2 months. According to data from the American Cancer Society, over 52,000 people are expected to die from pancreatic cancer this year. Wall Street predicts that sales could surpass $9 billions by 2032.
-- Earnings Flash (NTNX) Nutanix, Inc. Posts Q4 Adjusted EPS $0.60 per Share, vs. FactSet Est of $0.49
Paylocity director, 10% owner Steven I. Sarowitz sells 441 shares valued at $68,355
WISeKey files Form 3 for Chief Marketing Officer Alexander Sebastian Hirsch
Crypto prices
More
